<SEC-DOCUMENT>0001818382-22-000009.txt : 20220329
<SEC-HEADER>0001818382-22-000009.hdr.sgml : 20220329
<ACCEPTANCE-DATETIME>20220329070411
ACCESSION NUMBER:		0001818382-22-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220329
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220329
DATE AS OF CHANGE:		20220329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		22777343

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20220329.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6002fef0-76aa-4c68-b3e6-ffc681957d9b,g:38171b9e-bb5c-48f1-8ff6-a3c3ae0d17f6,d:181d9cebcee4420385edf148b399000c--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20220329</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY185Mi9mcmFnOjJkMWJkMWMzYjBmZTQ0OTE4NjA0NzE4Mjg0MTc2NjRiL3RhYmxlOjMxYjdlYzcwMjVjYjQ3YTNiZmIxM2EwMGQ0ZDg1ZTQwL3RhYmxlcmFuZ2U6MzFiN2VjNzAyNWNiNDdhM2JmYjEzYTAwZDRkODVlNDBfMS0xLTEtMS0xNzU1Mg_f756ac3d-ebb8-48e3-a60d-e64b0c3a3b0f">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY185Mi9mcmFnOjJkMWJkMWMzYjBmZTQ0OTE4NjA0NzE4Mjg0MTc2NjRiL3RhYmxlOjMxYjdlYzcwMjVjYjQ3YTNiZmIxM2EwMGQ0ZDg1ZTQwL3RhYmxlcmFuZ2U6MzFiN2VjNzAyNWNiNDdhM2JmYjEzYTAwZDRkODVlNDBfMi0xLTEtMS0xNzU1MA_e9080100-16b3-4e19-9773-4fa15babf5af">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20220329.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i407103d050984cffbad474e97686059f_D20220329-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i181d9cebcee4420385edf148b399000c_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk2_343d5c0c-73ae-4af5-93ff-2470da200d87">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk5_e8e0ed7c-5bf6-4cf0-9d4b-907bfe387a3f">March 29, 2022</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk3_4c8ba192-3478-4a26-8a45-2625b0f29055"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk4_14a10fa9-68b7-4df3-bf87-0b7b9ecc11de">Humacyte, Inc.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6NTNkOTJlM2M4MTZhNDU5MTk5NzFjMWZlYzY4MzlkZDkvdGFibGVyYW5nZTo1M2Q5MmUzYzgxNmE0NTkxOTk3MWMxZmVjNjgzOWRkOV8wLTAtMS0xLTE3NTcx_83a7e5f0-8cb0-4484-bbc1-edb792b89efd">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6NTNkOTJlM2M4MTZhNDU5MTk5NzFjMWZlYzY4MzlkZDkvdGFibGVyYW5nZTo1M2Q5MmUzYzgxNmE0NTkxOTk3MWMxZmVjNjgzOWRkOV8wLTEtMS0xLTE3NTcz_89655eb0-b81f-4215-98ca-99ef427c5f49">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6NTNkOTJlM2M4MTZhNDU5MTk5NzFjMWZlYzY4MzlkZDkvdGFibGVyYW5nZTo1M2Q5MmUzYzgxNmE0NTkxOTk3MWMxZmVjNjgzOWRkOV8wLTItMS0xLTE3NTc1_3d5df07f-a5e8-4a79-8c8e-92497be443ab">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18wLTAtMS0xLTE3NTc3_d568c1a5-1b3b-49d4-a052-a44e9321741c">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18xLTAtMS0xLTE4MjA1_d79e0fdd-6d0b-43cc-b621-85e0ef8271de">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18xLTEtMS0xLTE4MjA3_a94d6dfe-ba89-47ad-98b3-27432028be75">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18xLTItMS0xLTE3Njk3_5d4a9ef9-b3bf-442c-b6f8-a817eb456e17">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODAx_04420796-33dd-4388-b03e-674bb358513a">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODA1_63c5e4d3-0247-4390-9103-1fcf83b481b9">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8wLTAtMS0xLTE3NTkx_f2dc15f2-1cdf-4d5f-80c0-8d6e92504d47">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8xLTAtMS0xLTE3NTkz_3fba1679-2b1e-40a8-8566-33e2741d9db6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8yLTAtMS0xLTE3NTk2_b3529f24-d26a-41d5-81a6-9187bbdaa761">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8zLTAtMS0xLTE3NTk5_7ace0724-9432-45e0-bd73-c3d7238a1daf">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i407103d050984cffbad474e97686059f_D20220329-20220329" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8xLTAtMS0xLTE3NjAz_5efafd32-2054-4402-983a-44fdcc53a92c">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i407103d050984cffbad474e97686059f_D20220329-20220329" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8xLTItMS0xLTE3NjA1_fdfb9906-a77f-48d4-872b-85a199e338b2">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i407103d050984cffbad474e97686059f_D20220329-20220329" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8xLTQtMS0xLTE3NjA3_ea7a6b61-8f5c-4d2f-b646-55ea9a26b116">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8yLTAtMS0xLTE3NjAz_9677a16a-9463-4213-8462-7e24a8d58cea">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8yLTItMS0xLTE3NjA1_1157d5ea-d84a-43f2-915d-9028e99453d9">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8yLTQtMS0xLTE3NjA3_3735867c-14c6-4801-b0e6-b1fad553c4c9">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODA2_1ec1a235-d4f9-49e4-8fb0-9f67d03c09a6">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODA3_b38c6f33-98e7-4c1f-9981-f337be49dc23">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i181d9cebcee4420385edf148b399000c_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i181d9cebcee4420385edf148b399000c_7"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm">Press release, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm">29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20220329xexx991.htm">.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i181d9cebcee4420385edf148b399000c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20220329xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i66ff55c7d476440aa882af2cb86aee71_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:center"><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:210px"></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">--</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advancing late-stage clinical and preclinical programs of the Human Acellular Vessel&#8482; (HAV&#8482;) and other engineered tissues across several indications</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">--</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">--</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">--</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">--</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conference call and live webcast at 8&#58;00 am ET today</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">--</font></div><div style="margin-top:19pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DURHAM, N.C. &#8211; March 29, 2022 &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ending December 31, 2021, and highlighted recent corporate accomplishments.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We are proud of the significant progress Humacyte made in 2021, advancing our first-in-class regenerative medicine platform and universally implantable human tissues product candidates that we believe have the potential to transform the treatment of acute and chronic disease,&#8221; said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. &#8220;We were pleased to expand the body of data supporting the potential of the HAV in our vascular clinical programs. In addition, we have pushed forward our preclinical small-diameter cardiovascular surgery product candidates and our biovascular pancreas tissue construct. We look forward to the expected completion of our late-stage clinical studies of the HAV for vascular trauma and arteriovenous (AV) access for hemodialysis as we work toward bringing these innovative engineered tissues to market.&#8221;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2021 and Recent Corporate Highlights</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Program Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Advancement of the Phase 2&#47;3 trial of HAV in vascular trauma has continued and 50 patients have been enrolled in the study. To date, results observed in this non-blinded trial include a very low rate of infection (approximately 2%), no reports of amputation related to the HAV, and high patency rates. Humacyte also continues to build upon its strong relationship with the U.S. Department of Defense and, if FDA approval is received, expects to supply HAVs for use in treating military personnel as a result of this collaboration. The Company expects to file a Biologics License Application (BLA) for this indication in 2022 or 2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s Phase 3 trial of the HAV for AV access for hemodialysis is nearing completion of enrollment, with more than 210 patients currently enrolled out of a target of 240. The Company currently expects to file a BLA for this indication in 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continues to work closely with its strategic partner and major shareholder Fresenius Medical Care (FMC), a leader in kidney care services, products and value-based care, providing what Humacyte believes are major market insight and commercial launch advantages</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In advance of completion of the Phase 3 trial, five-year data from a Phase 2 clinical trial of patients receiving the HAV for access in hemodialysis were published in the journal EJVES Vascular Forum. Results showed long-term durability and usability of the HAV during the five-year follow-up period, with no reports of infection or immunogenicity.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In preparation for the potential market launches of the HAV in trauma and AV access, during 2021 Humacyte successfully deployed its commercial-scale manufacturing system for the production of HAVs. Data from a Phase 2 clinical trial for AV access in hemodialysis using HAVs produced using the Humacyte&#8217;s commercial-scale manufacturing systems demonstrated 12-month efficacy similar to HAVs produced in the development-scale systems previously used. In 2021, the FDA agreed to the use of HAVs produced in the commercial-scale system to supply the Company&#8217;s ongoing clinical trials in the United States. The 12-month data were presented at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Broader Pipeline Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s HAVs are continuing to be used under an Expanded Access Program (EAP) authorized by the FDA, for patients with vascular conditions including critical limb ischemia and peripheral arterial disease (PAD). To date, more than 20 implants of the HAV have been completed in the US under this program. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">Results from the first series of eight compassionate use cases where the HAV was used for treatment of critical limb ischemia and acute trauma were presented at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society. In this high-risk group of patients having no alternatives for vascular reconstruction, five of the bypasses performed with the HAV currently remain patent (with follow-up times ranging from four to 20 months after surgery).  No instances of HAV infection were noted, highlighting the potential of the HAV to expand limb salvage options for patients who have exhausted current revascularization options.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.75pt">Results from a case study of a patient who received the HAV as a replacement for an infected synthetic iliofemoral bypass graft were published in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Journal of Vascular Surgery&#58; Cases, Innovations and Techniques</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This was the first use of the HAV in the treatment of a patient with an infected prosthetic vascular graft, performed in April 2019 under the EAP. Twenty-two months post-implantation, the patient has resumed regular physical activity and no signs of infection of the HAV implant have been observed. Now approaching three years post-implantation, the patient discusses her experience and resuming normal life after receiving the HAV. The full story aired on NBC15 WMTV Madison on March 27, 2022, and can be viewed here&#58; </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Arterial transplant recipient celebrates three years of survivorship.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The first preclinical study of the use of the Company&#8217;s small-diameter (3.5mm) HAV in coronary artery bypass grafting (CABG) was presented at Advanced Therapies Week in January 2022. The HAV maintained patency and researchers observed host-cell remodeling and regeneration in a non-human primate (baboon) model, which is considered to be highly predictive of human outcomes.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Positive results from a preclinical study of the small-diameter HAV for use as a pediatric Blalock-Thomas Taussig (BTT) shunt in a primate model simulating pediatric heart disease were presented at the American Heart Association&#8217;s Scientific Sessions 2021. Each of the HAVs remained patent during the study and researchers observed repopulation with vascular cells.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical results of the Company&#8217;s biovascular pancreas (BVP), an HAV coated with islets, were presented at the 18th World Congress of the International Pancreas and Islet Transplantation Association in October 2021. In the preclinical study, researchers observed that animals implanted with the BVP normalized glucose over time, supporting the BVP as a potential approach for transplanting pancreatic islets that produce insulin for the treatment of type 1 diabetes.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Throughout the fourth quarter, the Company and outside investigators presented results at ten additional scientific and medical meetings, highlighting progress in the development of the Company&#8217;s broad pipeline and proprietary bioengineering platform. Included among the presentations were results related to use of the HAV in vascular trauma, AV access and peripheral arterial disease, preclinical research related to the biovascular pancreas for Type-1 diabetes, lung regeneration, and the Company&#8217;s biomanufacturing platform.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">As part of the Company&#8217;s preparation for potential commercial launch of the HAV in vascular trauma and AV access for hemodialysis, market research was conducted with 60 vascular surgeons in the U.S. Receptivity towards adoption of the HAV was high, with conclusions including&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">Approximately 80% of trauma bypass patients would be eligible for HAV if approved by the FDA. Reduced operative time without additional infection risk was perceived to be the biggest benefits of the HAV.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">Surgeons surveyed were highly receptive to the HAV for use in AV access if approved by the FDA due to the potential infection resistance and potential for reduced catheter exposure due to rapid useability for dialysis access.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">In December, the Company appointed three Surgical Key Opinion Leaders (KOLs), Alan P. Kypson, M.D., FACS&#59; Luigi Pascarella, M.D., FACS&#59; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), to advisory positions. In these roles, the KOLs lend their expertise and support to guide the education and clinical advancement efforts of the HAV and help identify opportunities to advance the Company's early-stage complex tissue constructs pipeline and platform.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter and Year Ended 2021 Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company reported cash, cash equivalents and short-term investments of </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$225.5 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2021, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$39.9 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2020. The increase in cash, cash equivalents and short-term investments resulted from the </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$242.4 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in proceeds from the August 26, 2021 merger with Alpha Healthcare Acquisition Corp. (the &#8220;Merger&#8221;) and related PIPE financing, partially offset by </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.8 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net cash used in operating, investing and other financing activities during the year. The Company believes that the cash, cash equivalents and short-term investments are adequate to fund operations through the end of 2024, past the Company&#8217;s current expected timelines for potential approvals of the HAV in vascular trauma and AV access for hemodialysis.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Revenue was </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$177.0 thousand</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021 compared to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$124.0 thousand</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2020, and was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. Revenue in all periods related to grants supporting the development of the HAV.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021 compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.2 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2020, and were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$61.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$54.1 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. The current-year increases resulted primarily from increased personnel, external services and materials expenses designed to support expanded research and development initiatives, the development of the commercial-scale manufacturing process, and support of clinical studies.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">General and administrative expenses were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021 compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2020, and were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$21.1 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. The current-year increase resulted primarily from non-cash stock compensation expense related to hiring leadership personnel, increases in professional fees and insurance costs related to the completion of the Merger and transition to being a public company, and additional personnel and recruiting costs associated with company growth.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Other net income (expenses) was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$64.2 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021 compared to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($0.5)&#160;million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2020, and was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$54.7 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021, compared to ($1.9) million for the year ended December 31, 2020. The current-year increase in other net income resulted primarily from non-cash gains related to the remeasurement of the contingent earnout liability associated with the Merger.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Net income was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021 compared to a net loss of </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.2 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2020, and the net loss was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.5 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2021, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$66.5 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2020. The current-year increase in net income for the fourth quarter and decrease in the net loss for the year, resulted from the increase in other net income described above.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after the filing of its Annual Report on Form 10-K with the SEC, the Company expects to file a Post-Effective Amendment to its Form S-1 registration statement that was declared effective on October 25, 2021 (as amended by Post-Effective Amendment No. 1, which was declared effective on November 24, 2021). The filing of the Post-Effective Amendment is not a new registration of securities but is filed solely to update the Form S-1, including with respect to the Company&#8217;s audited financial statements for the year ended December 31, 2021. Certain stockholders whose shares are registered on the Form S-1 are subject to the terms of an Investor Rights and Lock-up Agreements, which includes restrictions on transfer until the termination of applicable lock-up periods.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Date&#58;</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tuesday, March 29, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453 International&#58; 1-201-389-0920 Conference ID&#58; 13728056</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Humacyte</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.Humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the Company&#8217;s cash runway, the initiation, timing, progress, and results of our preclinical and clinical trials&#59; the anticipated characteristics and performance of our HAVs&#59; our ability to successfully complete, preclinical and clinical trials for our HAVs&#59; the anticipated benefits of our HAVs relative to existing alternatives&#59; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; our rights and obligations under our partnership with Fresenius Medical Care&#59; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology&#59; the timing or likelihood of regulatory filings and approvals&#59; timing, scope, and rate of reimbursement for our HAVs&#59; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the impact of COVID-19 on Humacyte&#8217;s business, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those included under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, filed by Humacyte with the SEC. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">###</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">Humacyte Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">LifeSci Advisors LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">+1-617-435-6602</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">Humacyte Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Heather Anderson</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">6 Degrees</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">919-827-5539</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">handerson&#64;6degreespr.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i66ff55c7d476440aa882af2cb86aee71_57"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>December 31,</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Revenue</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,341&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,597&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,130&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,013&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,804&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,796&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,471&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,091&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21,627)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,672)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81,208)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(64,600)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expenses), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,772&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses (net)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expenses), net </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,212&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,731&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) and comprehensive income (loss) </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,585</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,212)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,477)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(66,524)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.81)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.54)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,003,506&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,765,688&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,970,398&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,765,688&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share, diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.81)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.54)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,743,854&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,765,688&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,970,398&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,765,688&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i66ff55c7d476440aa882af2cb86aee71_50"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,929&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,340&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,449&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,978&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,261&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,688</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,592&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,050&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,233&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,090&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164,359</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,016</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity (deficit)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,747&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,573)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,096)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit )</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350,317)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,688</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20220329.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6002fef0-76aa-4c68-b3e6-ffc681957d9b,g:38171b9e-bb5c-48f1-8ff6-a3c3ae0d17f6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20220329" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20220329">
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20220329_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20220329_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20220329_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20220329_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6002fef0-76aa-4c68-b3e6-ffc681957d9b,g:38171b9e-bb5c-48f1-8ff6-a3c3ae0d17f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20220329.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended" id="i1fe2a66a40324fc2bb7a55c4bd670585_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5610960a-809c-420b-8444-314002632f7d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_DocumentType_5610960a-809c-420b-8444-314002632f7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c6025fff-355a-4b88-8da6-482e6db32d3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_DocumentPeriodEndDate_c6025fff-355a-4b88-8da6-482e6db32d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b4fe93a3-a7d7-4fc4-9f59-29991cb6548e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityRegistrantName_b4fe93a3-a7d7-4fc4-9f59-29991cb6548e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6ae35521-6c22-4a9d-9039-fb7eb7d24f40" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6ae35521-6c22-4a9d-9039-fb7eb7d24f40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_82e2e546-a354-4805-bcfd-80fe7f505100" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityFileNumber_82e2e546-a354-4805-bcfd-80fe7f505100" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a2e9abf8-ea2b-4d89-beec-00e6c0cad9c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityTaxIdentificationNumber_a2e9abf8-ea2b-4d89-beec-00e6c0cad9c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_72a10e0e-f694-4dac-b6f2-a8649883260f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressAddressLine1_72a10e0e-f694-4dac-b6f2-a8649883260f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_def443da-8ebd-4350-99b2-52e8291360f6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressCityOrTown_def443da-8ebd-4350-99b2-52e8291360f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f14dfc4e-f08e-4960-9e7c-2eb6b96b455a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressStateOrProvince_f14dfc4e-f08e-4960-9e7c-2eb6b96b455a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4c0ac823-a076-405d-ba46-c618295162b7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressPostalZipCode_4c0ac823-a076-405d-ba46-c618295162b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4728e2a7-d3f4-4f89-a9cf-84af44e01c96" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_CityAreaCode_4728e2a7-d3f4-4f89-a9cf-84af44e01c96" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86d09279-5725-4fb1-a9f5-7f1f81496b42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_LocalPhoneNumber_86d09279-5725-4fb1-a9f5-7f1f81496b42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cb891c58-0450-4b54-9eaf-c218451436fe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_WrittenCommunications_cb891c58-0450-4b54-9eaf-c218451436fe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0bb60c97-8f8b-431e-8165-ef241f613cd5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_SolicitingMaterial_0bb60c97-8f8b-431e-8165-ef241f613cd5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_cfa34618-883e-47bd-a37d-0fcb7c0706fc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_PreCommencementTenderOffer_cfa34618-883e-47bd-a37d-0fcb7c0706fc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e717da0d-9749-4430-b919-0a47e27b9582" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e717da0d-9749-4430-b919-0a47e27b9582" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f4196741-c3c3-4557-8c2d-72ebb67f22aa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_Security12bTitle_f4196741-c3c3-4557-8c2d-72ebb67f22aa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8d749cb8-265c-4ca7-a8e3-61d0fa78ecb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_TradingSymbol_8d749cb8-265c-4ca7-a8e3-61d0fa78ecb1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7a9580e3-bb0e-4087-8cc8-2a29f4e405cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_SecurityExchangeName_7a9580e3-bb0e-4087-8cc8-2a29f4e405cc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2a899951-e775-4378-a271-61045d71c7f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityEmergingGrowthCompany_2a899951-e775-4378-a271-61045d71c7f3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_402bcf6f-3e9c-421b-b868-3cd43c5bb63b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityExTransitionPeriod_402bcf6f-3e9c-421b-b868-3cd43c5bb63b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6937649b-01d9-41f6-98cd-2b8432406c4b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityCentralIndexKey_6937649b-01d9-41f6-98cd-2b8432406c4b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_97bb6a51-d648-45eb-81a7-21178778e351" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_AmendmentFlag_97bb6a51-d648-45eb-81a7-21178778e351" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:to="loc_us-gaap_ClassOfStockDomain_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:to="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9821b9c3-62f9-4df5-a5e3-9b74f3e971b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:to="loc_us-gaap_CommonStockMember_9821b9c3-62f9-4df5-a5e3-9b74f3e971b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_055bdb2e-9d4b-4988-a3bf-7b2e9ddd82b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:to="loc_us-gaap_WarrantMember_055bdb2e-9d4b-4988-a3bf-7b2e9ddd82b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20220329_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6002fef0-76aa-4c68-b3e6-ffc681957d9b,g:38171b9e-bb5c-48f1-8ff6-a3c3ae0d17f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityAddressStateOrProvince_19bc9b4c-fd82-41f0-8ec8-7e6ab14ff45d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c6e9deca-2bc4-4a08-9f3e-619d73f62a3e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c64d0311-e164-437b-90aa-bf9847ac229c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cfa7a313-25df-4ab2-acfb-eadfdd6ca3d0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_49e23864-9758-46d5-9693-827bea841fe4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a9ca7111-0199-417c-8e5b-82b4134924c2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b9ff456b-888f-4f8c-ba0b-67128d627a28_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e352823c-f185-4cea-8206-4692fb1e77c7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0d4cdead-2981-4012-b537-e100938365fc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_719e602f-1ad3-47ca-b9d8-b43fe8356473_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_57c45257-aa7b-4a54-807f-836c2efd9b55_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_d11672c4-e9bf-4ed0-9f01-60361759c273_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5d9589d6-a50b-4e1b-883d-eedeec65f2f7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0876358c-4702-49ad-95fe-452ebedd6c2f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_11fbbc6f-c390-4698-b8b7-8f9cc939bb49_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3934206d-ad4f-4480-9e2e-99da5029f6d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_359ceb54-2dc1-4e87-9331-54bcfad1abe2_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b1cdaee3-8dba-4a6d-95bc-dc95e7bee089_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4cd79364-362d-4925-a9be-9c722d822540_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e28b4a31-035b-4b19-a42e-d821602c2563_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e0605042-a0b5-4abb-abd4-312b925a114c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_eda77702-c171-4bb7-b93b-60be7ee94c85_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_772effdc-642c-487b-8e19-8bf58ed98426_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_86de58b4-d7a3-4f60-bf57-5e27f841abda_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_99736103-9652-42c1-bf29-43d44ba3aa57_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_deab04e3-c07c-479c-98ce-2d8ea38f00e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_c8fbf227-e29f-4499-b1ca-977e54d50861_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_816af6f5-b8ca-4613-b47d-3031a5707e15_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1da4bb7c-0a13-46c8-90cb-e9b40ef32c95_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20220329_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6002fef0-76aa-4c68-b3e6-ffc681957d9b,g:38171b9e-bb5c-48f1-8ff6-a3c3ae0d17f6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20220329.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b986694b-72a3-4daf-a4a6-52163c71c80a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b986694b-72a3-4daf-a4a6-52163c71c80a" xlink:to="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ec7a5bd-08b3-4fbe-8a75-eebf014578c7" xlink:to="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9821b9c3-62f9-4df5-a5e3-9b74f3e971b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:to="loc_us-gaap_CommonStockMember_9821b9c3-62f9-4df5-a5e3-9b74f3e971b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_055bdb2e-9d4b-4988-a3bf-7b2e9ddd82b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5008c869-5a78-4125-bed0-fd7dc3987327" xlink:to="loc_us-gaap_WarrantMember_055bdb2e-9d4b-4988-a3bf-7b2e9ddd82b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_c722ce43-c716-4546-8481-1c045306296a" xlink:to="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5610960a-809c-420b-8444-314002632f7d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_DocumentType_5610960a-809c-420b-8444-314002632f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c6025fff-355a-4b88-8da6-482e6db32d3c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_DocumentPeriodEndDate_c6025fff-355a-4b88-8da6-482e6db32d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b4fe93a3-a7d7-4fc4-9f59-29991cb6548e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityRegistrantName_b4fe93a3-a7d7-4fc4-9f59-29991cb6548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6ae35521-6c22-4a9d-9039-fb7eb7d24f40" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6ae35521-6c22-4a9d-9039-fb7eb7d24f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_82e2e546-a354-4805-bcfd-80fe7f505100" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityFileNumber_82e2e546-a354-4805-bcfd-80fe7f505100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a2e9abf8-ea2b-4d89-beec-00e6c0cad9c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityTaxIdentificationNumber_a2e9abf8-ea2b-4d89-beec-00e6c0cad9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_72a10e0e-f694-4dac-b6f2-a8649883260f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressAddressLine1_72a10e0e-f694-4dac-b6f2-a8649883260f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_def443da-8ebd-4350-99b2-52e8291360f6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressCityOrTown_def443da-8ebd-4350-99b2-52e8291360f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f14dfc4e-f08e-4960-9e7c-2eb6b96b455a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressStateOrProvince_f14dfc4e-f08e-4960-9e7c-2eb6b96b455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4c0ac823-a076-405d-ba46-c618295162b7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityAddressPostalZipCode_4c0ac823-a076-405d-ba46-c618295162b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4728e2a7-d3f4-4f89-a9cf-84af44e01c96" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_CityAreaCode_4728e2a7-d3f4-4f89-a9cf-84af44e01c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86d09279-5725-4fb1-a9f5-7f1f81496b42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_LocalPhoneNumber_86d09279-5725-4fb1-a9f5-7f1f81496b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_cb891c58-0450-4b54-9eaf-c218451436fe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_WrittenCommunications_cb891c58-0450-4b54-9eaf-c218451436fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0bb60c97-8f8b-431e-8165-ef241f613cd5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_SolicitingMaterial_0bb60c97-8f8b-431e-8165-ef241f613cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_cfa34618-883e-47bd-a37d-0fcb7c0706fc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_PreCommencementTenderOffer_cfa34618-883e-47bd-a37d-0fcb7c0706fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e717da0d-9749-4430-b919-0a47e27b9582" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e717da0d-9749-4430-b919-0a47e27b9582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f4196741-c3c3-4557-8c2d-72ebb67f22aa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_Security12bTitle_f4196741-c3c3-4557-8c2d-72ebb67f22aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8d749cb8-265c-4ca7-a8e3-61d0fa78ecb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_TradingSymbol_8d749cb8-265c-4ca7-a8e3-61d0fa78ecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7a9580e3-bb0e-4087-8cc8-2a29f4e405cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_SecurityExchangeName_7a9580e3-bb0e-4087-8cc8-2a29f4e405cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2a899951-e775-4378-a271-61045d71c7f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityEmergingGrowthCompany_2a899951-e775-4378-a271-61045d71c7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_402bcf6f-3e9c-421b-b868-3cd43c5bb63b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityExTransitionPeriod_402bcf6f-3e9c-421b-b868-3cd43c5bb63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6937649b-01d9-41f6-98cd-2b8432406c4b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_EntityCentralIndexKey_6937649b-01d9-41f6-98cd-2b8432406c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_97bb6a51-d648-45eb-81a7-21178778e351" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d2b6b536-3e41-405c-b9b4-91d4d1253aad" xlink:to="loc_dei_AmendmentFlag_97bb6a51-d648-45eb-81a7-21178778e351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MRELR"2*Q9G*LK#!7,QK65WIJ7<UI7E-:O59%!;DFNF)L\ ^ 2BG!/;2D4;C
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MH6G.!3UMTVF.ZG( "B*RO>25^/333\M/T"('J7#050TNO/#"\A-?\4K'[3
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M9&O@_JA1J$[0:UL,3)M <SJCORV$+@\B?%@58B1CE(N7N2K8Q4IOI:""AHG
M_.(2BL8#[F6FQQJ;VK3,G-"2HYEK\"<@$M32BHX@(A5@U&C=EWLL\^V/Z[_R
M28.M4[9)PWIOE 2WBP!SYLS3G_[PYW#$/_D=#P=_?NJIIT(X>BSWJ@'X07B&
M,XB)M'SVV6?+7\\%:# DIG< F(VT $\;!D8B0.CXU6#.,#0P4M#S<Z C(86X
MGBS.P""O,,"<O%V%A$8*PS"\G82=>+AC\KX*^C2W"@)>+AB-H9?TZ02L=,1?
MGP H#YV#E0HZ,HS)*@MAG)D=/%V6JZ EY?-[O[VN'J8J<#]HP>MOE,M5I^H
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MXYJ:7K^6QM2KK0DV:Y]SPS4V _]8N0MFFO0P'2W13F76.<I,NH3S#>4-\H\
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M&=\KGYR.N\7#.7@<1T]O1\#S<_2TD@$W_/U5=^S; YY>2!MZX6;HRW^^/ =
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MZ7Q;8V#:C7+[/ #:LY%#_3'9X(F;K,AL#1*OU=,(4<.5,ZYC',(SX8B#61'
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MR;+'K6 %$#::$%<4(H&>?O G4@))@+7]F%/T[!AS_V6&!E 6^OHDW*?[[!2
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M:&:"5SU$,CH[5^6/6_1;#5:B$?F6^P0LAU\X1(_$"GW&(C(KBTII&,)&SSZ
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M^27,GS\_?'3\P@LO# /1\.'#RP< @#+$A:D+G3CP[&&P5Q4'P8@=0.-E $)
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M60&,YLK^"NF0GO<[GD$T>]J(=L8?'L&$OW$'&7S^YW_^)_ L_,JFK;\ ]?=
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M"-/[U)UGEA?0B-FMYTT?ILRD18=U[2&."$R6/3A#RT804RG2<&'AZ8+)]7!
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I7^%7^#?!KP+X5_@5?H5?X=\"TO\'GVM_Z3P1[XL     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140231290474536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Mar. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 29,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>huma-20220329_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20220329.xsd" xlink:type="simple"/>
    <context id="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="i407103d050984cffbad474e97686059f_D20220329-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY185Mi9mcmFnOjJkMWJkMWMzYjBmZTQ0OTE4NjA0NzE4Mjg0MTc2NjRiL3RhYmxlOjMxYjdlYzcwMjVjYjQ3YTNiZmIxM2EwMGQ0ZDg1ZTQwL3RhYmxlcmFuZ2U6MzFiN2VjNzAyNWNiNDdhM2JmYjEzYTAwZDRkODVlNDBfMS0xLTEtMS0xNzU1Mg_f756ac3d-ebb8-48e3-a60d-e64b0c3a3b0f">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY185Mi9mcmFnOjJkMWJkMWMzYjBmZTQ0OTE4NjA0NzE4Mjg0MTc2NjRiL3RhYmxlOjMxYjdlYzcwMjVjYjQ3YTNiZmIxM2EwMGQ0ZDg1ZTQwL3RhYmxlcmFuZ2U6MzFiN2VjNzAyNWNiNDdhM2JmYjEzYTAwZDRkODVlNDBfMi0xLTEtMS0xNzU1MA_e9080100-16b3-4e19-9773-4fa15babf5af">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk2_343d5c0c-73ae-4af5-93ff-2470da200d87">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk5_e8e0ed7c-5bf6-4cf0-9d4b-907bfe387a3f">2022-03-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk3_4c8ba192-3478-4a26-8a45-2625b0f29055">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2Nzk4_14a10fa9-68b7-4df3-bf87-0b7b9ecc11de">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6NTNkOTJlM2M4MTZhNDU5MTk5NzFjMWZlYzY4MzlkZDkvdGFibGVyYW5nZTo1M2Q5MmUzYzgxNmE0NTkxOTk3MWMxZmVjNjgzOWRkOV8wLTAtMS0xLTE3NTcx_83a7e5f0-8cb0-4484-bbc1-edb792b89efd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6NTNkOTJlM2M4MTZhNDU5MTk5NzFjMWZlYzY4MzlkZDkvdGFibGVyYW5nZTo1M2Q5MmUzYzgxNmE0NTkxOTk3MWMxZmVjNjgzOWRkOV8wLTEtMS0xLTE3NTcz_89655eb0-b81f-4215-98ca-99ef427c5f49">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6NTNkOTJlM2M4MTZhNDU5MTk5NzFjMWZlYzY4MzlkZDkvdGFibGVyYW5nZTo1M2Q5MmUzYzgxNmE0NTkxOTk3MWMxZmVjNjgzOWRkOV8wLTItMS0xLTE3NTc1_3d5df07f-a5e8-4a79-8c8e-92497be443ab">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18wLTAtMS0xLTE3NTc3_d568c1a5-1b3b-49d4-a052-a44e9321741c">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18xLTAtMS0xLTE4MjA1_d79e0fdd-6d0b-43cc-b621-85e0ef8271de">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18xLTEtMS0xLTE4MjA3_a94d6dfe-ba89-47ad-98b3-27432028be75">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZGI0ODJmYTM5YzNhNDYzMWFiZjFmODY0ZDc0MGNjNGMvdGFibGVyYW5nZTpkYjQ4MmZhMzljM2E0NjMxYWJmMWY4NjRkNzQwY2M0Y18xLTItMS0xLTE3Njk3_5d4a9ef9-b3bf-442c-b6f8-a817eb456e17">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODAx_04420796-33dd-4388-b03e-674bb358513a">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODA1_63c5e4d3-0247-4390-9103-1fcf83b481b9">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8wLTAtMS0xLTE3NTkx_f2dc15f2-1cdf-4d5f-80c0-8d6e92504d47">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8xLTAtMS0xLTE3NTkz_3fba1679-2b1e-40a8-8566-33e2741d9db6">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8yLTAtMS0xLTE3NTk2_b3529f24-d26a-41d5-81a6-9187bbdaa761">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6ZTMxMGJlZWZlNzkyNDQ0OGIxODczNjU4OTdjYTI5NzUvdGFibGVyYW5nZTplMzEwYmVlZmU3OTI0NDQ4YjE4NzM2NTg5N2NhMjk3NV8zLTAtMS0xLTE3NTk5_7ace0724-9432-45e0-bd73-c3d7238a1daf">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i407103d050984cffbad474e97686059f_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8xLTAtMS0xLTE3NjAz_5efafd32-2054-4402-983a-44fdcc53a92c">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i407103d050984cffbad474e97686059f_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8xLTItMS0xLTE3NjA1_fdfb9906-a77f-48d4-872b-85a199e338b2">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i407103d050984cffbad474e97686059f_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8xLTQtMS0xLTE3NjA3_ea7a6b61-8f5c-4d2f-b646-55ea9a26b116">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8yLTAtMS0xLTE3NjAz_9677a16a-9463-4213-8462-7e24a8d58cea">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8yLTItMS0xLTE3NjA1_1157d5ea-d84a-43f2-915d-9028e99453d9">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia169613b53ca42b1a72b3baa54f6c64a_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGFibGU6MWRlNGU2MTgwYTY4NDA4YWI0ODgwMzIxZDhiYjgxYjUvdGFibGVyYW5nZToxZGU0ZTYxODBhNjg0MDhhYjQ4ODAzMjFkOGJiODFiNV8yLTQtMS0xLTE3NjA3_3735867c-14c6-4801-b0e6-b1fad553c4c9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODA2_1ec1a235-d4f9-49e4-8fb0-9f67d03c09a6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i60134a26077f44ef8bd44368dad245bf_D20220329-20220329"
      id="id3VybDovL2RvY3MudjEvZG9jOjE4MWQ5Y2ViY2VlNDQyMDM4NWVkZjE0OGIzOTkwMDBjL3NlYzoxODFkOWNlYmNlZTQ0MjAzODVlZGYxNDhiMzk5MDAwY18xL2ZyYWc6MWVhMzllNTA4NGI0NDQyNDg4ZTQ3OGM5MzAzYmRiYzcvdGV4dHJlZ2lvbjoxZWEzOWU1MDg0YjQ0NDI0ODhlNDc4YzkzMDNiZGJjN18yMTk5MDIzMjU2ODA3_b38c6f33-98e7-4c1f-9981-f337be49dc23">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^0B7)T:XE7X&*67(\S:M?&"\>^_B"P)Q64!<G@<QXTK(@$R2@$#L*GEPI4,
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MN+:[,#+-/V@MI#$RSD]#SF!'8QO _TLIS>'"?B,K/G$._P902P,$%     @
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ A#A]5)E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "$.'U4QUN5)^($  #N%   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ A#A]5)^@&_"Q @  X@P   T
M             ( !)0T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "$.'U4
MEXJ[',     3 @  "P              @ $!$   7W)E;',O+G)E;'-02P$"
M% ,4    " "$.'U4&445]3<!   G @  #P              @ 'J$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ A#A]5"0>FZ*M    ^ $  !H
M         ( !3A(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ A#A]5&60>9(9 0  SP,  !,              ( !,Q,  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ?10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20220329.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="huma-20220329.htm">huma-20220329.htm</File>
    <File>huma-20220329.xsd</File>
    <File>huma-20220329_def.xml</File>
    <File>huma-20220329_lab.xml</File>
    <File>huma-20220329_pre.xml</File>
    <File>huma-20220329xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "huma-20220329.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "huma-20220329_def.xml"
     ]
    },
    "inline": {
     "local": [
      "huma-20220329.htm"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20220329_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20220329_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "huma-20220329.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20220329",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20220329.htm",
      "contextRef": "i60134a26077f44ef8bd44368dad245bf_D20220329-20220329",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.humacyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20220329.htm",
      "contextRef": "i60134a26077f44ef8bd44368dad245bf_D20220329-20220329",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001818382-22-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-22-000009-xbrl.zip
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M)95)FF29Q/-]ES)B$&X9NJE+FO42ZS:;/F\)OI!_93#8>! &7I#:O.?"$"R
MTEQ3G.D!Y;,4UD"T.0AIDM3]LS3RNI5QD!3VYU4.HEXOZF<%>3\?2VN[OUFZ
M&RA>Q6926;=T674UU:-$<65J**[J4JH17_=T0M_69E[0&+2R]-5O9&F9N946
M-*T2Z&.Y4I;M[\_LC"NYL-AFILCU@CYN<V$+E8DV2#^, I:VRR 8_K>0U=O_
MF PH\'DW+D'K_'/>R=VN:-R"WMPH3:->61VDA;SQO-R+PB@N_U/*_GWP888@
MP'M!."G_IP%[G""'C]!IU*/]_^PEH%&#ZAT'?EXQ"::\+ -\V;?1#&#H1BCA
M\PGD4/_[G[(N?5B&=0%*L:R8AD&K7_9@GWD,4*;4#?F\@AO%L+P8H WI(.'E
M^8</<YTWU_QQUNC#\J3%"H*1F@8>#6>#9./EQ;>+6Y3R!4YA&U,V'WE67,R*
M2BF[6V:914NZOU@JRC=EI:SO>%YAMD3YKD [F)58H$\%M; R\=O]0RP:BH41
M6_9A0!D+^JVRA.2LC]M!2ME*W(\0:32 .</*K%OZIT40<P5#C%4,4<3BG3O'
MC5H5G34JC=K9@Q#E): ]JQV<GQXWCFMGJ.)44>VO@S\JSE$-'=1M^_CL[+CN
MO. 4I(VF<$&3-N!.&O7W4+5X4$2*I!'K7K WP9L=R=XE62!,E$1AP'Z58N^P
M\'7\_Q40^F']U)Z)@^>S4N>^Q]S+\I*VZ/A$N9PT+SS=OOC>MJ=AZ#0JQ#DZ
MEL0X3K5%H+U:/[(U>UJ9-GNG =B=U^SH.V%_? DOE?#:[43CRXO:M'X!-F*U
M)8$]"FV/I7JU#;!ZI#GM3NTJV*='7SJ.;$[LAAC[>&IWSA5GVE6N5*(RS9,\
M;*B48T)]#5NJ[V.%&!*CBB0QTRCLF_C/NS;EUJ"6LA%J 4\^K3D-=%K[6C]M
MO" 'W@S<K\,X&8(^C-((G7%/^"F1K*+Z*9*U=^P]BORMGT*CS07HPSA( ^BU
M-O;:M-_BJ.*E #Z2+95LD2"\HYMF<Q JOP#VE ^B.$7OYM\Y!:6?)RGBU^(4
M(\Z*.7M?_FW<ZVMF?]1RJV39U\;@%PR6<=H6S3"C$SP!@#'O_W>S.^V*FUSB
MS/ PK+..B>=+V&+$Q99DN#Y738.J?F'?IK'71HJUEYTV/2GGVVE!SZ@%;9TZ
M\^P'*J>\%23B-"MUH.2_F[K5*^*9+I4M!:O$,+%87&Q2HF%%5S17\A5+TK3=
MIOS632%7,J&RY%,+ZZ9K8,)\%;N^:6#)-5R+>YXL,U[8_V/8H]XDY7OHN.\5
MUQY@;,*"MT5M>%<;4]!R!&8(;2&^P0A$$Y0,N"?\J0P%?12D"0*]")2'^/U.
MLFR[9'E-ZZPJ1455-UKG;>F6/ 0K[D.!^2XK@['8Y[O$LKKJ^8+_?D^;]%M4
M!."G40S621;JDIW#'$3#?AI/#B*V;#>(R!EQ(I+R01Q=BWY>J<%P&+A'Y[K3
M<+KUQI?05FQB-R[;3O5<$]+)F1YV[(M+@*5)H,_N9;4[:_,=QM+ZEXU(MI5O
MFMT[GS:GK;'3JTE.HSN&>:CVA3V^['WO.)T62,33;OV[.3II5-)9F(;J-+SQ
ME:E2@VM@6IB>*V%"3()=UY,Q9ZYA*:YI<9^!9<E#.J(QOU>VS<A@A^$_P_##
M(.30NPMB<(>M/\?6VB*V3J],2]<T#HCJFK*/B2)KV#(]BBU 4Z(8GN832QP+
MRUBU-/5^:WB'KANB:X..CV='ZE[&E'>XNS'N'B_BKGRE,HWYDN%CJG%A\!D6
M\%R38TLAEN%RV!OJ%O9-#<N&KAJ:]4/D?6JU G3&WV]]9"C\+A/S*(I1E+9Y
MC#K#.$A8D#N1(S\[&@H6U8*L:MRB_6":?7__'%3]@NLA H6"1(2D("$L4$YQ
M;VV6Q\73XED1U7J#,)KP.-OF94ZS=N*;&T#*ZS* %+5(B/;DELHS=4NLHBD_
MR"Q>QEE]$YP-N7]GS6^D[1;&(3R[,*XP%O,DF?TY 0#D5RR(+X^$8^Y+K]FP
MM>;4 4'<G-H7A\%EY[!7KS:ERZHGV4=.QSFR5P3QH-OL?"-V[U*,V;$5$,0B
MU/GB2\^^:!*G<]IUIM]&3<66 ,95DT>]8IIN>C(%0>NJ+B86(YA*FH(I;(RE
M*K)!9*^PKVB*AFHT29$3Q6D;'= X@CVGZ _8\A&=((W\V-.W :.^Z]MYE$C/
M+AN]!&]_(:5T1@ '\+$>-Z+1:S;\?Q,5C!>H@,!<Y"MF6%SR&<,ZDX *5,_#
MKJ[(V-2X!/NB&)FKNSJ,V[2W][2&U#K&_G+H^NR'X$M(FVF[]?AK'%T'V96T
M'>;^%'-KBYBK7E&+,)WY'+O4M# Q*,.6Z:I8,8@*ZV^ZW- *^\[!SOI_(IS]
M&B4I#2^#0>Z%W6'L3S%VP?3O=-4KC1%J<=_"H'#XF!!%\%K?Q-24#>X23>>R
M 1J'8<CJPZW^C73IK;/_9J@E#AP',7#"8$!#Q,?<&Z;!M3B'!#.0)V_-Z@4:
M@BDP_EBC]D?Q(C^)HMT6*^G=,W(MH1%68DY?+9]ZFE"&>K4ROI+$-1W#TK&J
M@I)'5-/$KJ1RK!O$=57-U&25%O8M^8Z?\?VS*T0G$1#CUW;4?\TG(4^V5?*5
MKGH:)TS%DD(,V"I+PI8LJ5CV/=]476+*KE785V456[IZOX1X>8J_)[[D-L;H
MW_\TP;[^D*"4AWP@, #U,Q380R #PJ%@Y(@"!:]PR9>/H=N,N3E1BBH#<0M0
M,/-'W!5[D?TYC&) I5D 4)R=LL-7FDMHV!D?Y<'0#"7"9D&A\(KD4<0;;]$+
MS>V@S;TN2ML<T<$@CD#5$(<-;C1&+@^CD9B;*!0K@$S\)_*#4*!@D  ^IKS/
M8,YI!-/N#<.4]GDT3,()2F@:)/XD:SEK$+FPC[/CB;S+A3"J(?0#Z]F?S,O\
M*(3!13L1O! (7W]2?L!*;I57^T<^9*4H&<J3>Y\MO:@KYC.'W_RRD^(".A:=
M)[^F,SZC'+Z(@Q207!PX#?NS4Y=D2S-A_)KAU[#']A%(ZXO+T)EVH?XW 0^,
M[TV=SCFI-UBGV3C6G.GYJN$7VM/:J-D#F'KG:KV1C4>:,%=G:BM.HZ4YBM.V
MP<AS[D37=,=7OL(\6?,5+'L,##^F^=B4/ F;3.>6HDF$$3#\HK?A7EN/OS,D
M@SDL8AD:+%P9.AT"-R.*-F.4Z?)5''$#YYULH(/#4Z2H4A$JKC&?=C2^GL;/
MHBPE <!H@^0#\1?N"/S1!#Y>(?#IE>J[5-8-6'M7YIA(U,2FI@NCBRL&D9G%
M7/V-$_@MAJ'>#,7N4K=,*):5!0)?NF!W0]X$9'=6<T?A&U/XUY@+"2ZR%647
MA876&M=]7]C5.TI_)*5/5BA=N7)53;%\A6"FZ!0#:6O8E*D.EKIIN"ZCU-#E
M-T[I@&G86T"UG\ITF3"LO'/?;T;W>=T=Y3^6\H^39,CC'?T_!?U/5^A?NS*H
MQ\&8)=@BJH*)QB7L,D/%GLH,136IS$1*NQW]+]&_"CK1.V\S^I_5_86CD6WS
MC+SABV4OX<M;L ESYQJ/.5M".CD3-C,G&R#8]OK4+*MH$O-1-^7DHKFA\^MA
M9432G_ZBW&L#5MW,6_FF;O4U1#+F/$^(UT:>2'KX *FUQ$;>Q'+$-#N&.IOT
MW"A\]Z 8A#>W&,[L4GB&&GPNNZ,^&K4#KYU%'-SRXH=H[C,.FS'@]?)IJ^(Y
M'AZ ]9CLMHM^NUS8363%S>CS%:OL]L5IZ!R=*W:C-6HVFL2I5DCS0IR/MT;V
M]'A\"6,U.ZUQL[.JLD?CRZ-SZ;+1!%@_MQV1X[K:;HM0K'JU,K4[ /_1EP#F
M$=QQSL%<KC3N4Y^!MBX2 F)") 5;I@K&._&9YVDJM12OL)\GYD59EM<]-* Q
MNJ;AD*-_9;J=C 8B$6W[URZ_;L 7=@3Q8X*8L>6<*^^H80-J6 Q"K,A7/O-=
MRY)T3 W#Q\1D!)N&XF)3H[)E<54U7:6P_\>Y7=DA^C9P_KFEG.?E64U](&3Q
MJ\]Z\/MHX=LB+:A7G!I4=W7QI(YX7(<I/G9UHF--X]2BBN[*LI[G!'1HPNC?
MN71 -HV[/$4G)S^.+?^9ZD.];BN.AGV&9^CJ>9S[_EO!_\>D@M]I/K^ WY,[
MFH^E&P9L \46T561)T'%)M$5;'"%4)-IIL=I8?^4,\Y[F=]CEM ^V<LU_5$[
M@A]'^8\B+#OV@B2KZ(O;UWV>:T3",EA4GQ!-$>#BK#X7D=U>5NE?LES4I$?(
ME9_2RB8"9T=O.\7J*8EM1;&29<U@(#@P,PD8%ZH/9H:L,6Q)BLDMBV@JLW+%
MZF)' =M( 3N-ZQF(9$7C4@U5,W7#PS+Q=+ ^)!F[$M>Q*_N4:;!QQ+-^4>/:
M\N.+XSX3)V4<N1/D96') %<71"W/\IZLQ P'229)8:XMX8P$ZAVE;7'@-A!Q
MQ#1!C/LP1):6,8^?D[3YR<=*\%R>OEI%[T0\NO$ABZ&;5PZRA(X#D=!1A'[G
MIW9@%"IK^EJ7$_NF4W&"=]MNH=OBED>(U]8O\7+L_F\+&?@]B23F<S[*IGR0
MSWA=M$ :#U^G_OUDMW.4*YE[,E54#3/B6YA8G(#5Z$K8\G6#2:HG611LQ?%C
M,V^_%#?R?\!?Q&V<M<PJN'.WH0VLB(?<$\_B]J/L%'8(FK^H!3@[NT$A7C -
MLLL1^4-4F14AQ@HG8O#L.5W!UOHP-RB)^358#U KZ-.^)^()J>>)/)"BLGC*
ME=&8)?G=";9R!'S[_, [>G,4O,BYBF^;LL>-F\7.D^Z_K2"@)Z-K]<I534_W
M515;)C<P\60?6Y8I8_A)I&.SF*>H/PKHV;:0@M<1C++R\-<# U(VNNF\^.#<
M(,IIH1SSD(J;Y7>>H+L%,X-/NFU"W20*A^G]31YR$WOU5;O-'M4CA7F;=GSK
M:F]Q[,:<=C'U8= R#4=TDA1*S_SRWF\36.NO5AZGO(>4HJ04T2E/AF&:Y0ZH
M@T"919^!6$"'-Q+C( ())@H>=H<4Y![L9%G57TPPU_MH^4F//;2<;QY,@V0(
M4H^" !09% "S.4TRH0QB,;N]"&MS*SOCV6H)F9N7),!&X.M0I+7Z>YBE<\]6
MSQ^&(1*/KZ!<;E>YES^2J<H9*'(158#"!Y,;)7\9 OC!'\;](&D+\(3!T [<
M($66592%;,Z:' SC6,0.SAZI$5D.YY<O!0RWJ1ZA#["+.-@WH(/</,B[L3FQ
M+?LI3-J@?_-^>R;S:6:YY;-;O/F<:TWYHM$TI5Y[5BV-]H3'%;9'Z%@N1\)Q
M"V7B/K4"T <A9]EG^4.VSZ 1 1OC&8G<:$3FAC;=GM@[VLMQX)UH,!MFL?)L
MM/=[0F%;VK3%W1+6J5#L9K=D[[W?-3-1%T?..EY5WO9$# H?Y"\39.OABA7+
MT%!<S.6IF#Z@-0 Q>[G 6X8F&0)IT1E :Y!I,[YL%-8@H/ 284"ZF'II.1GV
M "$G'[:(>5I%"2CXED7>O'.;\\X9M29;;KB(]\3FH#[$M_!JE#'9* *6/4/,
MI*893QXS:0!2:9L]L/ <5SEN%)G?[8V>8> =_'NAM!/#_!WJ7TD_^22[\J*Q
MBE6>>'$P6%+Z?N4X?C%0I:@MA:K\)%KE11%V/=L4.MC&"/*L9TZ_>UE]_]FN
MQ.3 ,>[-4I.7,P5'U *8Z%J]8*;>?7AQ %$[%FZG-M@6-_ZD,1^/+4LNMM->
M=MOG5K??0RQ3[CZ6Z.N?669?O8F9O(W]4*PW,8W,1GX3,WD;LRAFL[@K\]:[
M,&7R(Q_F'6'F9_]^32 ^=Q_/$(>X71=298EL<03-NK7J!8R%_*62H44 #?I*
M6QP="W<UD+/(M5JE*<V?&GDGW'U,N'W$D5S0S_POQYDIC/[Z?'J"V.P]YX53
M_9^'7_PV?_Q:!\RV9-E;U;X?=1X@2UMX(+ UV1?/CH^<2N/\M/;:?,1?%PZP
M\_/UOX=!///-;>JT77,PSX;A!'ET* [3,^=[GK11#.-RE,"&04&4O^OJ\C8-
M?>$X%1UE8G9603B@AWUHDW5'AVD[BF%R[$UZWS2I:,B/N['\P[O%19D\?2)$
M4C0EZ^EAU8N6NIF3<4.?WKT"UMKF)!CKO4PBCO>@V:CMH6/G8(T8?)AB^0A7
MW+U5[R:"?Z+W9;9+Z0-UA9=7SDC?4I:5SY/RO=-Y]+M9+S>=/-RJE)1 SP01
M4"FB,RJ$RV/2/#T%E:R_B/A4CLB76&$1KGX_RKR]^6X;'KV:A<NNTVV"*:]F
M1@?M@/L+1]KU[-F0> _E!0?SJ 14Y=<\C 99UJI9I>S0NP%F4S*,UZ'1R]NS
MVV*Z*O>;KB4W8A/XTTY[X?[_ U!+ P04    " "$.'U4)'?X\)D"   '"0
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M>$<7;N*4_7&>NYN3B M)GO)EP;P2YCA8YY,AX+@G,AI+/$ @E((*-+AH0S8
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M>(V*1:'"&4]2Y>_!7P,*TVKQ!D?-#0P\#)CP4WH'B.M,\?) 1MG129X,4C\
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M(D8]H@U!U(11OEKLRTN&.=W)C/,!)(F+@^7. ZUCT1>>25^ @V(R)I3#03_
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M<W"F[%"J49<D?:_Y]*8VKSAJ;J[?I6Y);ZWMC*>VF,$CA!,%U&A2492>,UX
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M-ARO+V8\:C:&9-.&(K<6X=4:#[S&K>ESCMB+0M'IEX90EZN'5:/I5E)JXW:
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MKB]<"3AS_=3[!YD5_>#?V62]XNSX220I?GH<BX G_I58F":?H4BAP,Z_P@<
M\#19_94-YP\_)NG1 .+NG#%3_'<0>5/XSR@9!Z_^/U!+ 0(4 Q0    ( (0X
M?534_P=)ZQ8  $>C   1              "  0    !H=6UA+3(P,C(P,S(Y
M+FAT;5!+ 0(4 Q0    ( (0X?50D=_CPF0(   <)   1              "
M 1H7  !H=6UA+3(P,C(P,S(Y+GAS9%!+ 0(4 Q0    ( (0X?53KZ$7_MP@
M % ^   5              "  >(9  !H=6UA+3(P,C(P,S(Y7V1E9BYX;6Q0
M2P$"% ,4    " "$.'U4F/0UB4<-  !I>   %0              @ ',(@
M:'5M82TR,#(R,#,R.5]L86(N>&UL4$L! A0#%     @ A#A]5 $_$+P^"
M\$   !4              ( !1C   &AU;6$M,C R,C S,CE?<')E+GAM;%!+
M 0(4 Q0    ( (0X?537(\%I12P  *.Z 0 8              "  ;<X  !H
M=6UA+3(P,C(P,S(Y>&5X>#DY,2YH=&U02P4&      8 !@"- 0  ,F4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
